Latest Pharmaceuticals News

Page 11 of 89
Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.
Victor Sage
Victor Sage
26 Aug 2026
Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.
Ada Torres
Ada Torres
26 Aug 2026
Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.
Ada Torres
Ada Torres
26 Aug 2026
Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.
Ada Torres
Ada Torres
25 Aug 2026
Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.
Ada Torres
Ada Torres
25 Aug 2026
Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.
Victor Sage
Victor Sage
25 Aug 2026
Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.
Victor Sage
Victor Sage
24 Aug 2026
Island Pharmaceuticals has commissioned a second manufacturing run of its antiviral Galidesivir, aiming to stockpile up to 800 treatment courses by late 2026 to support rapid response to the fast-spreading Bundibugyo Ebola outbreak and biodefence efforts.
Victor Sage
Victor Sage
21 Aug 2026
IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.
Victor Sage
Victor Sage
20 Aug 2026
Motio Ltd (ASX:MXO) reported a solid FY26 with revenue rising to $9.2 million, a 31% jump in cash EBITDA to $2.5 million, and a net profit before tax of $1.7 million. The company enters FY27 debt free and with forward revenue up 28%, signalling operational leverage and growth potential.
Elise Vega
Elise Vega
20 Aug 2026
Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.
Ada Torres
Ada Torres
20 Aug 2026
Emyria has cleared a key operational hurdle by resolving Authorised Prescriber capacity constraints in Perth and Queensland, enabling a planned expansion of treatment days in Q4 2026 through the recruitment of 15 new therapists.
Ada Torres
Ada Torres
20 Aug 2026

Browse the archive

Full archive